Comparison of Critical Flicker Fusion vs. Automated Visual Fields in the Detection of Early Glaucoma
The purpose of this study is to evaluate if critical flicker fusion is a more reliable method for detection of early glaucoma compared to automated visual fields in comparison to subjects without evidence of glaucoma or optic nerve disease.
Emergency Department (ED) Use of Nebulized Budesonide as an Adjunct to Standardized Therapy in Acutely Ill Adults With Refractory Asthma: a Randomized, Double-blinded, Placebo-controlled Trial
To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED patients with refractory acute asthma helps improve forced expiratory volume at one second (FEV1) and decrease the need for hospitalization.
Implementation of a Postpartum Note Reminder and Factors Associated with Postpartum Glucose Tolerance Screening
4区 · 医学
作者: Domingo, Anna ; Fogel, Joshua ; Raffel, Ryan ; Gesner, Timothy ; Itzhak, Petr
Although reminder systems are used to increase provider adherence, we are not aware of any real-time reminder systems for provider adherence to postpartum glucose tolerance testing. We studied whether a reminder in the electronic medical records affects provider ordering of a postpartum glucose tolerance test. We also studied whether any demographic, medical history, prenatal, or delivery variables are associated with patient attendance to a postpartum visit and patient completion of the postpartum glucose tolerance test when ordered.
This was a retrospective study of 246 women diagnosed as having gestational diabetes mellitus who completed prenatal care and delivered at a suburban public safety-net hospital.
Implementation of the real-time postpartum note reminder system significantly improved provider adherence to postpartum glucose screening recommendations from 58.1% to 75.0% (P = 0.01). Delivery complications were significantly associated with increased odds for postpartum visit attendance (odds ratio [OR] 3.80, 95% confidence interval [CI] 1.63-8.86, P < 0.01). Increased gestational age at first prenatal visit was significantly associated with decreased odds for postpartum visit attendance (OR 0.93, 95% CI 0.87-0.99, P < 0.05). Speaking Spanish was associated with an increased odds for completion of the postpartum glucose tolerance test when ordered (OR 2.88, 95% CI 1.24-6.70, P = 0.01).
We recommend that hospital managers include a reminder system in the electronic medical record. Providers should focus counseling on the potential future risks to the mother, in addition to encouraging continued adherence to postpartum care. Providers also should counsel those who present later to prenatal care about the importance of obtaining postpartum glucose tolerance tests.
2021-05-11·Journal of the American College of Cardiology
COVID-19: racial disparity and cardiovascular comorbidities that predict mortality
作者: Omeh, Demian Jideofor ; Wenn, Peter ; Castillo, Andres ; Roper, Ashley ; Ponto, Michelle K. ; Yang, Yerin ; Wilson, Yea ; Lin, Xiu Qing ; Cassagnol, Manouchkathe ; Hai, Ofek ; Wu, Wenchen ; Zeltser, Roman ; Makaryus, Amgad
Background: There have been reports of significant racial disparities in COVID-19 infection outcomes. Despite this claim, there is a relative paucity of literature regarding racial and ethnic variations. We aimed to evaluate the relative significance of race/ethnicity, socioeconomic status, and other comorbidities on COVID-19 outcomes. Methods: This is a retrospective study of 812 confirmed COVID-19+ patients admitted to a safety-net hospital between 3/1/20 and 6/31/20. Patients were stratified by self-reported racial/ethnic groups. Median household income (MHI) was estimated from the US census bureau website based on zip codes of residence. Demographics and prevalence of comorbidities were compared using independent t-test and χ2. Multivariate regression anal. was used to determine predictors of mortality. Results: 501 patients (62%) were included in the anal. The racial breakdown was: Non-Hispanic Whites 98 (19.6%), vs. Non-Whites 403 (80.4%; Non-Hispanic Black 126 [25.1%], Hispanic 250 [49.9%], East Asian 9 [1.8%], South Asian 13 [2.6%], American Indian 1 [0.2%], and Other 4 [0.8%]). White patients were older (71.1 vs. 57.6, p <0.001), more likely to have high MHI (39.8% vs. 7.2%, p < 0.001). Non-Hispanic Whites had more comorbidities: CHF (p = 0.008), CAD (p = 0.004), A-fib (p = 0.003), and higher Charlson comorbidity index (CI; p <0.001). The two groups had similar gender, ICU admission, ventilation requirement, hypertension, diabetes, hyperlipidemia, chronic kidney disease, and CVA (all p = NS). Non-Hispanic Whites had higher death rate (36.7% vs. 26.3%, p = 0.04). After controlling for age, gender, CI, and other risk factors, there was no statistically significant difference in mortality in the two groups. Age, male gender, CI, and ventilation requirement were independent predictors of mortality irresp. of race. Conclusion: In our sample, race/ethnicity was not an independent predictor of mortality in patients with COVID-19, after controlling for other variables including socioeconomic status. Our study further underscores the important role that safety net hospitals play in providing quality care to communities in need.
We may develop medications effective against COVID-19, but can we distribute them equitably?
作者: Kersten, Daniel J. ; Makaryus, Amgad N.
There has been significant press regarding possible pharmaceutical agents with efficacy against the novel coronavirus disease 2019 (COVID-19). These medications may provide critically ill patients a greater chance of recovering from the virus. As the COVID-19 pandemic continues to escalate in the United States, concerns have been raised that persons of lower socioeconomic status, especially in urban environments, may be at greater risk of complications.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Axim Biotech, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced it has appointed Henry D. Perry, MD to its recently established Medical Advisory Board. He is the third member of the of the Medical Advisory Board that also includes Chairman Joseph Tauber and Laura Periman.
A recipient of the Life Achievement Award from the American Academy of Ophthalmology, Dr. Perry is recognized as one of the US’ leading cornea and refractive surgeons. He serves as Senior Founding Partner, Ophthalmic Consultants of Long Island as well as Chief, Cornea Service, Nassau University Medical Center, New York. He has won numerous Best Doctor awards and was recently recognized as one of the top 150 Ophthalmologists in America by "Newsweek" magazine in 2021.
“I’m thrilled,” said John W. Huemoeller II, AXIM® Biotech Chief Executive Officer. “Dr. Perry brings decades of valuable clinical and research experience that rounds out the exceptional depth of expertise of our Board’s first two members.”
“We’ve invited the nation’s top clinical surgical and research experts in ophthalmic pathology focused on Dry Eye (DED) and Ocular Surface Disease, and they continue to accept,” Huemoeller added. “I strongly believe this reflects the valuable DED diagnostic intellectual property and assets we are acquiring as well as the potential medical and economic value of our DED division to diagnose the millions of previously undiagnosed patients suffering from DED.”
Henry D. Perry, MD Summary Bio
Dr. Perry is the Senior Founding Partner of Ophthalmic Consultants of Long Island, and Chief, Cornea Service at Nassau University Medical Center, East Meadow, New York.
He earned his medical degree with honors from the University of Cincinnati College of Medicine and completed his residency at the Nassau County Medical Center and the University of Pennsylvania Scheie Eye Institute. Dr. Perry went on to earn fellowships in Ophthalmic Pathology at the Armed Forces Institute of Pathology in Washington D.C., and in cornea and external disease at the cornea service of the Massachusetts Eye and Ear Infirmary, Harvard University. He then served two years in the United States Army as Major, Medical Corps at Fort Sam Houston, San Antonio and Fort Dix, New Jersey.
Dr. Henry Perry is recognized as one of the leading cornea and refractive surgeons in the US and has written over 200 papers and chapters on corneal and refractive surgery and ophthalmic pathology. He has given over 500 invited lectures around the US and abroad including several named lectureships. He has served as medical director of the Lions Eye Bank for Long Island at Northwell Health since 1987. He serves as Senior Editor for the Journal “Cornea” and is the winner of the Honor Award, Senior Honor Award and Life Achievement Award from the American Academy of Ophthalmology. He has won numerous Best Doctor awards and was recently recognized as one of the top 150 Ophthalmologists in America by “Newsweek” magazine in 2021.
Dry Eye Disease Market
Recent estimates of the prevalence of dry eye disease are that over 26 million people in the United States and over 300 million globally suffer with dry eye disease. The prevalence is growing in both young and old adults, making it more urgent that clinicians are better able to diagnose and treat DED. As many as two-thirds of patients with symptoms of dry eye have never been diagnosed by their physician. Diagnosing DED is a challenge because of the multifactorial nature of the disease, with symptoms similar to other ocular surface conditions. It is well known that there is often a discordance between signs and symptoms, highlighting the need for more sensitive and accurate diagnostic tools.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the landscape of diagnosis of SARS-CoV-2 (COVID-19), dry eye disease (DED) and Oncological indications. AXIM’s COVID-19 neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and ophthalmological conditions such as DED. For more information, please visit .
The statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2021 and other reports we the SEC, which are available at . Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Public Relations Contact:
AXIM Corporate Contact Info:
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
Investor Relations Contact:
The board chair of Nassau University Medical Center resigned May 28, accusing the East Meadow, N.Y.-based hospital's governance of not making necessary changes at the financially struggling hospital, according to Newsday.
Robert Detor has chaired the Nassau Health Care Corp., the entity that oversees the public hospital, since January 2020. In a May 25 letter sent to Nassau County Executive Laura Curran and obtained by Newsday, Mr. Detor said he "hoped to change NHCC's course, but it has become clear to me I can no longer align my service on the board with my professional, moral and ethical standards."
Mr. Detor said "issues of serious concern were identified and presented to the board" based on an independent review, and he couldn't accept the outcome of the board's deliberation. He called on the New York State Department of Health to review "not only the current circumstances, but the overall condition of the corporation's governance," according to Newsday.
Other leaders at the healthcare corporation and medical center disagreed with Mr. Detor's characterization of governance at the hospital.
Megan Ryan, the general counsel for the board, told Newsday that "there are no pending issues that require any investigation."
Anthony Boutin, MD, CEO and president of the medical center, told Newsday: "I am proud to say that NHCC is in the best financial situation it has ever been in. I am offended by these baseless allegations and inferences. I am working with my team to create a strategic plan over the next year to fortify NHCC's position in our community."
A March report from consultants Alvarez & Marsal found the medical center couldn't survive without closing its emergency room, issuing sweeping layoffs and selling its extended care facility, according to Newsday.
A man died March 22 after jumping from a window of East Meadow, N.Y.-based Nassau University Medical Center, according to the Nassau Daily Voice.
Nassau County Police Department officers were dispatched to Nassau University Medical Center at 3:40 a.m. March 22 after a report of a man who suffered serious injuries, according to the Nassau Daily Voice. A Nassau County Police medic pronounced the 34-year-old man dead outside of the Long Island hospital, according to police.
An investigation found the man broke a window on the medical center's eighth floor before jumping, according to police. He suffered self-inflicted fatal wounds, police said. The man hasn't been named, pending notification of his family, according to the Nassau Daily Voice.
The investigation is ongoing, according to the report.
Becker's Hospital Review reached out to Nassau University Medical Center for comment, but did not hear back before publication. This story will be updated as more information becomes available.